Avalo Therapeutics, Inc. (AVTX)
AVTX Stock Price Chart
Explore Avalo Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AVTX price movements and trends.
AVTX Company Profile
Discover essential business fundamentals and corporate details for Avalo Therapeutics, Inc. (AVTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Oct 2015
Employees
23.00
Website
https://www.avalotx.comCEO
Garry A. Neil
Description
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
AVTX Financial Timeline
Browse a chronological timeline of Avalo Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.66.
Earnings released on 13 May 2026
EPS came in at -$0.98 surpassing the estimated -$1.00 by +2.00%.
Earnings released on 23 Mar 2026
EPS came in at -$0.37 surpassing the estimated -$1.54 by +75.97%, while revenue for the quarter reached $79.50k , beating expectations by +34.75%.
Earnings released on 6 Nov 2025
EPS came in at -$2.19 falling short of the estimated -$1.67 by -31.14%.
Earnings released on 7 Aug 2025
EPS came in at -$1.92 falling short of the estimated -$1.43 by -34.27%.
Earnings released on 12 May 2025
EPS came in at -$1.25 falling short of the estimated -$1.07 by -16.82%.
Earnings released on 4 Apr 2025
EPS came in at -$7.95 falling short of the estimated $0.58 by -1.47k%, while revenue for the quarter reached $192.00k .
Earnings released on 7 Nov 2024
EPS came in at -$2.83 falling short of the estimated -$1.19 by -137.82%, while revenue for the quarter reached $249.00k .
Earnings released on 12 Aug 2024
EPS came in at -$14.07 falling short of the estimated -$6.70 by -110.00%.
Earnings released on 11 Jul 2024
EPS came in at -$141.14 .
Earnings released on 13 May 2024
EPS came in at -$5.98 falling short of the estimated -$1.18 by -406.78%, while revenue for the quarter reached $571.00k .
Stock split effective on 29 Dec 2023
Shares were split 1 : 240 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$26.19 surpassing the estimated -$261.90 by +90.00%, while revenue for the quarter reached $236.00k , missing expectations by -21.33%.
Earnings released on 3 Aug 2023
EPS came in at -$140.48 surpassing the estimated -$214.29 by +34.44%, while revenue for the quarter reached $643.00k , beating expectations by +28.60%.
Earnings released on 4 May 2023
EPS came in at -$202.38 surpassing the estimated -$230.95 by +12.37%, while revenue for the quarter reached $475.00k , missing expectations by -52.50%.
Earnings released on 29 Mar 2023
EPS came in at -$247.62 falling short of the estimated -$123.81 by -100.00%, while revenue for the quarter reached $896.00k , missing expectations by -75.18%.
Earnings released on 7 Nov 2022
EPS came in at $80.95 surpassing the estimated -$245.24 by +133.01%, while revenue for the quarter reached $14.95m , beating expectations by +1.09k%.
Earnings released on 4 Aug 2022
EPS came in at -$328.57 surpassing the estimated -$428.57 by +23.33%, while revenue for the quarter reached $1.03m , missing expectations by -12.94%.
Stock split effective on 8 Jul 2022
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 May 2022
EPS came in at -$571.66 falling short of the estimated -$400.16 by -42.86%, while revenue for the quarter reached $1.17m , beating expectations by +81.72%.
Earnings released on 2 Mar 2022
EPS came in at -$1.92 falling short of the estimated -$1.90 by -1.05%, while revenue for the quarter reached $219.00k , missing expectations by -78.49%.
Earnings released on 9 Nov 2021
EPS came in at -$485.91 surpassing the estimated -$543.07 by +10.53%, while revenue for the quarter reached $1.35m , beating expectations by +66.67%.
Earnings released on 2 Aug 2021
EPS came in at -$2.16 falling short of the estimated -$2.04 by -5.88%, while revenue for the quarter reached $3.36m , meeting expectations.
AVTX Stock Performance
Access detailed AVTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
